Regeneron answers rivals with data for new version of top-selling eye drug
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Roche Lucentis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.
Visiongain has launched a new report on the Global Pharmaceutical Contract Manufacturing Market Forecast 2022-2032: - Market Segment by Services...